换一批
换一批Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
第一作者：
I F,Khouri
第一单位：
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. ikhouri@mdanderson.org
作者：
主题词
急性病(Acute Disease);成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗体, 肿瘤(Antibodies, Neoplasm);抗原, CD(Antigens, CD);抗原, 肿瘤(Antigens, Neoplasm);伯基特淋巴瘤(Burkitt Lymphoma);女(雌)性(Female);糖蛋白类(Glycoproteins);移植物抗宿主病(Graft vs Host Disease);造血干细胞移植(Hematopoietic Stem Cell Transplantation);人类(Humans);男(雄)性(Male);中年人(Middle Aged);前体细胞淋巴母细胞白血病淋巴瘤(Precursor Cell Lymphoblastic Leukemia-Lymphoma);移植, 同种(Transplantation, Homologous)
DOI
10.1038/sj.bmt.1704435
PMID
14755312
发布时间
2017-11-16
- 浏览21
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
